Trial Profile
A study evaluating safety and efficacy of neoadjuvant axitinib therapy in renal cell carcinoma patients with inferior vena cava thrombus.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jun 2017
Price :
$35
*
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2017 New trial record
- 16 May 2017 Results presented at the 112th Annual Meeting of the American Urological Association